Abstract:Abstract BACKGROUND Chordomas, rare indolent neoplasms, mainly occur in the skull base or lower spine. Therapies, including surgery and radiotherapy, often fail to impede local recurrence. Though checkpoint inhibition therapy shows promise, recent immunotherapy trials failed to reach endpoints. Here, we aim to investigate the immunological landscape of chordomas using spatial and single-cell transcriptomics, and TCR/BCR profiling, elucidating cellular interplay and the intricate mechanisms governing the immunosuppressive tumor microenvironment. MATERIAL AND METHODS We generated a comprehensive single-cell atlas of the chordoma neoplastic landscape and its associated microenvironment, incorporating paired single-cell transcriptomic samples from blood and tumor cells of six patients, as well as single-cell BCR and TCR sequencing data. Utilizing scGEN, we integrated pre-annotated gene expression datasets and identified both established and novel antigen binding patterns by employing TCR Bidirectional Encoder Representations from Transformers (BERT). Moreover, we conducted GeoMx Digital Spatial Profiler (DSP) analysis by selecting regions of interest (ROIs) that encompass critical immunological and malignant niches. We also curated and quantified cell distributions in immunohistochemical staining for a total of 107 chordomas. RESULTS Utilizing pseudo-temporal mapping, we delineated the trajectories of CD8 and CD4 T cells in chordomas, spanning from blood to tumor stroma and encompassing naïve, memory, cytotoxic, and T cell exhaustion profiles. Through an integrated TCR profiling methodology, we observed extratumoral clonal expansion of cytotoxic and memory T cells in the blood, whereas the majority of intratumoral T cells with shared motifs exhibited terminal exhaustion. Leveraging TCR-BERT, we identified binding patterns exclusively enriched in exhausted T cell receptors' binding sites and uncovered shared motifs within the reactive tumor-infiltrating compartment, implying the existence of potential reservoirs for anti-tumor immunity. Investigating the cell-cell interactions driving intratumoral exhaustion, we identified M2 tumor-associated macrophages and a plasma cell phenotype-like subset upregulating TGFB and IL10 expression, referred to as regulatory B cells (Bregs). Spatial profiling substantiated the proximity of regulatory B cells and exhausted T cells within immunosuppressive niches, suggesting an underexplored mechanism contributing to tumor-derived T cell exhaustion. CONCLUSION Regulatory B-cells have been identified in the TME of various solid tumors, including colorectal, breast, cervical, and ovarian carcinomas. Our study emphasizes the role of regulatory B cells in the chordoma immune environment, providing crucial insights into novel immunosuppressive mechanisms and pathways leading to T cell exhaustion in chordoma.

Csig-35. Rab3B Dictates Mtorc1/S6 Signaling In Chordoma And Predicts Response To Mtorc1-Targeted Therapy

CMTM3 Suppresses Chordoma Progress Through EGFR/STAT3 Regulated EMT and TP53 Signaling Pathway

Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target

SMARCB1 Loss in Poorly Differentiated Chordomas Drives Tumor Progression

Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5

SIRT5 promote malignant advancement of chordoma by regulating the desuccinylation of c-myc

LncRNA NONHSAT114552 Sponges miR-320d to Promote Proliferation and Invasion of Chordoma Through Upregulating NRP1

Hypoxic Upregulation of IER2 Increases Paracrine GMFG Signaling of Endoplasmic Reticulum Stress‐CAF to Promote Chordoma Progression via Targeting ITGB1

MTNR1B loss promotes chordoma recurrence by abrogating melatonin-mediated β-catenin signaling repression

TGFB3 Downregulation Causing Chordomagenesis and Its Tumor Suppression Role Maintained by Smad7

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

The malignancy of chordomas is enhanced via a circTLK1/miR-16-5p/Smad3 positive feedback axis

Rationale for the Advancement of PI3K Pathway Inhibitors for Personalized Chordoma Therapy

JS07.4.A REGIONAL B-CELL MEDIATED IMMUNOSUPPRESSION IDENTIFIED THROUGH SPATIAL AND SINGLE-CELL TRANSCRIPTOMIC ANALYSIS OF CHORDOMA

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Clinical-proteomic classification and precision treatment strategy of chordoma

Long non-coding RNA LOC554202 modulates chordoma cell proliferation and invasion by recruiting EZH2 and regulating miR-31 expression

Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma

Clinical and molecular features of sacrum chordoma in Chinese patients

Organelle resolved proteomics uncovers PLA2R1 as a novel cell surface marker required for chordoma growth